Ann‐Lii Cheng
Author
Institution National Taiwan University
Past institutions National Taiwan University, National Taiwan University Hospital, Tianjin University, Eindhoven University of Technology, Shandong University +5 more
ORCID: Yes
H-index: 98
I10-index: 533
Works count: 1,266
Citations count: 67,310
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
2008 · Ann‐Lii Cheng, Yoon‐Koo Kang, et al. · The Lancet Oncology
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2020 · Richard S. Finn, Shukui Qin, et al. · New England Journal of Medicine
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
2018 · Masatoshi Kudo, Richard S. Finn, et al. · The Lancet